US 7765106

I'll search for authoritative information on US patent 7765106, including any 2026 CAFC activity.

Let me run a couple more targeted searches on current litigation/appeal status and the PTAB record.

Summary of US Patent 7,765,106

Search note: I searched Google Patents, RPX/Unified Patents PTAB databases, IPWatchdog/Duane Morris case coverage, and Federal Circuit reporters. I found no CAFC docket activity in 2026 involving this patent. Its CAFC history is from 2017–2018 (details below). Treat any statement about "2026 CAFC dockets" as unconfirmed for this number.

Bibliographic data (as listed in the authoritative text you provided)

Term/expiration discrepancy (flagged, not resolved): Google Patents lists an "adjusted expiration" of 2027-06-19 for this record, while the Orange Book listing reproduced in the Roxane complaint and in the FDLawBlog Orange Book appendix shows 06/16/2024 (use codes U-1009 in one source, U-1069 in the other). The front page of the granted patent (reproduced at docshare.tips) states the term was "extended or adjusted under 35 U.S.C. 154(b) by 1645 days" and that the patent is "subject to a terminal disclaimer." These sources do not reconcile cleanly; I cannot state the expiration date authoritatively.

Abstract (verbatim)

"A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug."

Independent claims in plain language

The patent has 8 claims, with four independent claims (1, 3, 5, 7) and four dependent claims (2, 4, 6, 8) that narrow the menu of distribution controls. Claims 1, 3, 5 and 7 are substantially parallel; the differences are noted below.

Claim 1 — Generic therapeutic method (computer-system-centric).
A method of treating a patient with a drug that is therapeutically effective but has abuse/misuse/diversion potential, in which:

1. Exclusive intake — all prescriptions, for all patients, from all doctors permitted to prescribe the drug, are received only into an "exclusive central computer system," carrying patient identity, drug identity, and physician credentials.
2. Exclusive database — the information must be entered into an exclusive computer database "for analysis of potential abuse, misuse, or diversion," such that authorization of every prescription happens only through that exclusive system/database.
3. Centralized tracking and pattern analysis — distribution is controlled by that system, which tracks all prescriptions and determines current and anticipated abuse/misuse/diversion patterns from periodic reports built on prescription data (patient, drug, physician credentials).
4. Selection of multiple controls — the method then selects multiple additional controls from a closed "group consisting of" list of roughly 30 items, e.g.: communicating prescriptions from physician to the central system; identifying physician name/license/DEA registration; verifying the prescription; obtaining patient information; verifying prescriber eligibility by consulting National Technical Information Services (NTIS) for an active DEA number and pending actions; providing printed materials to the physician; contacting the patient's insurer; verifying patient registry information; patient education and confirming it was received/read; verifying home address; USPS or commercial shipping; an at least 18-year-old designee to receive the drug; confirming receipt of the initial shipment; returning the drug to a pharmacy after two failed delivery attempts; investigating lost shipments; shipping to another pharmacy for pickup; single-site manufacture; controlled inventory release; questioning early refills; flagging repeat lost/stolen/destroyed/spilled prescriptions; one-month supply limits; periodic prescription rewriting; and making the database available to the DEA (including for cash payments and "inappropriate questions").
5. Filling authorization — the system authorizes filling a prescription that has been subjected to those controls and approved for shipment.
6. Noting risk — based on the analysis/periodic reports, the method records a potential for abuse, misuse or diversion by that patient.
7. Delivery to treat — the drug is delivered to the patient to treat them.

Claim 3 — Sodium oxybate / narcolepsy species claim.
Identical architecture to claim 1, but the drug is sodium oxybate, the patient is a narcoleptic patient, and the indication is daytime cataplexy. It reproduces the same ~30-item control group and the same authorization, risk-noting, and delivery steps.

Claim 5 — Database-centric variant.
Same seven-step architecture, but the "exclusive" element is recited at the level of the exclusive computer database "in a computer system" rather than an exclusive central computer system. All prescriptions from all allowed doctors and all patients are received only into that exclusive database, and authorization of every prescription occurs "only via the exclusive computer database."

Claim 7 — Parallel variant with different phrasing.
Same architecture again, with drafting differences: the doctors are those "allowed to prescribed [sic] the prescription drug" and the credentials are of "the medical doctor who is writing the prescription." The exclusive-system/exclusive-database requirement, the periodic-report analysis, the control group, authorization, risk-noting and delivery steps are the same as claim 1.

Dependent claims 2, 4, 6, 8 each narrow the applicable controls to a shorter subset: communicating prescriptions to the central system/database; identifying physician name/license/DEA registration; verifying the prescription; obtaining patient information; verifying patient registry information; providing comprehensive education to the patient; verifying the patient received/reviewed the educational materials; and requiring periodic prescription rewriting.

Drafting observation (literal reading, no auto-correction): the "group consisting of" lists use Markush-style language but are extremely long and functional, and claim 7 contains the typo "allowed to prescribed."

Litigation and validity history (relevant to "current status")

• PTAB — IPR2015-00546 (challenging the '106 patent): final written decision July 27, 2016 in which all claims were held unpatentable. The RPX Insight record lists the panel as Brian P. Murphy, Jacqueline W. Bonilla, Jon B. Tornquist, Susan L. C. Mitchell. Sources disagree on the petitioner name: Docket Alarm and RPX list [Amneal Pharmaceuticals LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%20LLC); the IPWatchdog footnote cites the parallel reports as Par Pharm., Inc. v. Jazz Pharm., Inc., No. IPR2015-00546. I cannot resolve that discrepancy from the material retrieved.
  • https://insight.rpxcorp.com/ptab/2606-wockhardt-v-jazz-pharmaceuticals-incorporated-[ipr](/resources/cost-of-inter-partes-review)-of-106
  • https://www.docketalarm.com/search/?q=&f=q_search_within-docket%3A(IPR2015-00546)+AND+court%3A(%22Patent+Trial+and+Appeal+Board%22)
• PTAB — IPR2015-01815 (Wockhardt Bio AG et al. v. Jazz Pharmaceuticals, Inc.), filed Aug. 27, 2015, instituted Oct. 30, 2015 as a joinder, terminated Jan. 3, 2017; the Board relied on the IPR2015-00546 final written decision.
  • https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2015-01815
• CBM2014-00161 — filed, not instituted (procedural) per the Google Patents "Family has litigation" record.
• *Federal Circuit — Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. July 13, 2018)* (No. 17-1671; Newman, Lourie, Reyna; opinion by Lourie). The court affirmed the PTAB's obviousness holdings across seven related Xyrem patents — 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,589,182; 8,457,988; 8,731,963 — finding the ACA materials (FDA Advisory Committee materials for Xyrem posted on an FDA website after the May 14, 2001 Federal Register notice, 66 Fed. Reg. 24,391) to be a publicly accessible "printed publication" and thus prior art. The court also upheld the Board's constructions of "periodic reports" (including irregular intervals) and "information identifying."
  • https://caselaw.findlaw.com/summary/opinion/us-federal-circuit/2016/02/02/[283543](/patent/283543).html
  • https://www.duanemorris.com/articles/case_study_jazz_pharmaceuticals_v_amneal_pharmaceuticals_1018.html
  • https://ipwatchdog.com/2018/07/24/prescription-tracking-patents-confirmed-unpatentable-after-ipr-appeal/
• District court actions listed on the Google Patents record include D.N.J. 2:10-cv-06108 (Roxane), 2:12-cv-06761, 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07755/07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, 2:18-cv-00029, and E.D.N.Y. 2:17-cv-04439. The Roxane complaint reproduces the Orange Book listing for 7765106, expiration 06/16/2024, and describes the '730/'106/'107 patents as "Xyrem REMS Patents" alleged to be improperly listed and obvious.
  • https://portal.unifiedpatents.com/patents/patent/7765106
  • https://www.labaton.com/hubfs/XYREM-Complaint.pdf

Points of uncertainty (stated explicitly)

1. No 2026 Federal Circuit docket entry for 7,765,106 was located. The controlling appellate decision I can verify is the July 13, 2018 affirmance at 895 F.3d 1347. I cannot confirm any 2026 appeal, petition, or docket activity for this patent.
2. Expiration date conflicts between Google Patents (adjusted expiration 2027-06-19), the Orange Book listing (06/16/2024), and the printed patent's 1,645-day § 154(b) adjustment with terminal disclaimer. I do not have an authoritative reconciliation.
3. Petitioner identity in IPR2015-00546 is reported inconsistently as Amneal Pharmaceuticals LLC versus Par Pharm., Inc.
4. The "claims" set as given is 8 claims total, with all independent claims reciting a closed "group consisting of" control list; I have summarized them literally without correcting apparent typographical errors in the claim text (e.g., "allowed to prescribed" in claim 7).
5. I did not retrieve a fresh USPTO PatentCenter/Patent Assignment record in this session; assignee and status fields are as reported by Google Patents and the Unified Patents portal, and Google Patents itself disclaims accuracy of the current-assignee list.

I'll research litigation involving US patent 7765106. Let me search multiple sources.

Let me gather details on specific cases and outcomes.

Litigation Involving U.S. Patent No. 7,765,106 ("Sensitive Drug Distribution System and Method")

Important framing notes before the list:

• U.S. 7,765,106 ("the '106 patent") issued July 27, 2010, to inventors Dayton T. Reardan, Patti A. Engel, and Bob Gagne, originally assigned to JPI Commercial LLC / Orphan Medical, and now associated with Jazz Pharmaceuticals, Inc. / Jazz Pharmaceuticals Ireland Ltd. It is a divisional of U.S. App. Ser. No. 10/322,348 (which issued as U.S. 7,668,730) and is part of the "’730 patent family." Its adjusted expiration is listed as 2027-06-19 (Google Patents; with pediatric exclusivity previously extending market protection to Dec. 16, 2024).
• The '106 patent claims are directed to a therapeutic method of distributing a sensitive drug using an exclusive central pharmacy/computer database (claims 1, 3, 5, 7, with dependent claims 2, 4, 6, 8). This matters because, in the related family, the Federal Circuit later held that the sibling '963 patent was a system (not method) claim and could not be Orange-Book listed — but the '106 patent as issued recites method claims.
• All '106 patent claims were held unpatentable in the PTAB/Federal Circuit track described below.

I could not access PACER directly; the case list below is drawn from the Unified Patents litigation/PTAB portal, DrugPatentWatch, Docket Alarm, RPX Insight, court complaints (paragraphfour.com, courtlistener.com, Labaton, Hagens Berman), and the Federal Circuit opinion. Where an outcome is not confirmed in a primary source, I say so.

A. ANDA / Hatch-Waxman District Court Litigation (D.N.J. unless noted)

Unified Patents' case list filtered to "Patents in Case: 7765106" returns the following ten district court cases, all listed as "Closed," all in the District of New Jersey except one in the Eastern District of New York:

Note on the related (non-'106) case: A later Jazz v. Lupin action, C.A. No. 18-8267 (ES)(JAD) (D.N.J.), filed April 24, 2018, asserted only the '306, '302, and '426 patents (not the '106) — included here only to avoid confusing it with case #7 above.

B. PTAB Proceedings (Post-Grant) on the '106 Patent

Related sibling IPRs decided alongside: IPR2015-00545 ('182), -00547 ('107), -00548 ('059), -00551 ('988), -00554 ('730), and IPR2015-01903 ('963).

C. Federal Circuit Appeal

• Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. July 13, 2018) (Appeal No. 17-1671). Panel: Lourie, Reyna, Tarantino (per Law360 report).
  • Outcome: AFFIRMED. The Federal Circuit affirmed the PTAB's obviousness findings invalidating claims of the seven Xyrem patents, including the '106 patent (U.S. Nos. 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,589,182; 8,457,988; 8,731,963). The court held the FDA "Advisory Committee Art" (Federal Register–linked FDA advisory committee materials) was a publicly accessible "printed publication" and thus prior art.
  • Result: "the result of inter partes review, as affirmed by the Federal Circuit, was the invalidation of all the patents in the '730 family." (N.D. Cal. antitrust complaint, Case 3:20-cv-04064.)

(Note: A separate, frequently cited Federal Circuit decision, Jazz Pharms. v. Avadel CNS Pharms., No. 23-1186 (Fed. Cir. Feb. 24, 2023), concerned the '963 patent's Orange Book listing — not the '106 patent. Do not conflate.)

D. Antitrust / REMS Litigation Citing the '106 Patent

These actions cite the '106 patent among the patents at issue but are antitrust (Sherman Act / REMS-abuse) claims, not patent infringement suits against the '106 patent:

• City of Providence, Rhode Island v. Jazz Pharmaceuticals PLC, N.D. Cal., 3:20-cv-04064-LB, filed 2020-06-18. Patents listed include 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; 8,589,182; 8,731,963; 8,772,306; 9,050,302; 9,486,426.
• Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals PLC, N.D. Cal., filed 2020-06-17 (terminated 2020-07-15 per DrugPatentWatch).
• United HealthCare Services, Inc. v. Jazz Pharmaceuticals plc, D. Minn., filed 2021-03-18 (terminated 2021-04-15) — antitrust.
• UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd., et al., E.D.N.Y. (docket 20-cv-03852), filed 2020-06-30 (class action against Jazz, Roxane/Hikma, West-Ward, Eurohealth) — alleges the '106 patent was improperly listed in the Orange Book and invalid (Labaton complaint; Hagens Berman complaint mirrors these allegations).
• Related "Xyrem" antitrust complaints that reference the '106 patent and the invalidation of the '730 family are likewise filed in N.D. Cal. and E.D.N.Y.

(Caveat: DrugPatentWatch's patent-page aggregation also returned unrelated cases — e.g., Anywherecommerce, Inc. v. Ingenico, Inc. — where "7765106" appears as a number string but the case does not involve this patent. I excluded those. I also excluded the Avadel/Lumryz and '306/'782 patent cases, which involve different patents.)

E. Summary

• Yes — there is substantial known litigation involving U.S. 7,765,106. It was asserted in roughly nine to ten Hatch-Waxman ANDA suits in the District of New Jersey (Roxane, Par, Ranbaxy, Watson, Wockhardt, Lupin, Ascent, Mallinckrodt) plus one Eastern District of New York action, all now closed, mostly via settlement.
• The patent was also challenged at the PTAB (CBM2014-00161 — not instituted; IPR2015-00546 and joined IPR2015-01815), where all claims were held unpatentable, a result affirmed by the Federal Circuit in Jazz v. Amneal, 895 F.3d 1347 (Fed. Cir. 2018).
• It also appears in the Xyrem antitrust/REMS MDL-style litigation (City of Providence, Blue Cross/Blue Shield, United Healthcare, UFCW Local 1500) as an allegedly improperly listed Orange Book patent.
• Google Patents' own litigation panel flags this patent's family as having extensive U.S. litigation, and lists D.N.J. dockets 2:10-cv-06108, 2:12-cv-06761, 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, 2:18-cv-00029, and E.D.N.Y. 2:17-cv-04439 — consistent with the Unified Patents table above.

Limitations on this answer: (1) I was unable to pull PACER dockets directly, so "Closed" reflects the Unified Patents status field rather than a judge-signed final judgment in each case; (2) the defendant in E.D.N.Y. 2:17-cv-04439 was not recoverable from the sources I could access and should be verified; (3) filing dates differ by ±1 day between sources (e.g., 2:10-cv-06108: Nov. 21 vs. Nov. 22, 2010) — I have flagged both. If you need certified per-case outcomes, I recommend pulling the PACER dockets for each case number and the PTAB Final Written Decisions for IPR2015-00546/IPR2015-01815 directly.

I'll start by searching for the PTAB proceedings associated with this patent and its family.

Excellent — I've found three PTAB proceedings and a Federal Circuit appeal. Let me nail down the details on IPR2015-01815 (Wockhardt), the FWD claim-level holdings, and the CAFC disposition.

PTAB Proceedings — US 7,765,106 ("Sensitive Drug Distribution System and Method")

Source-note / conflict flag: The structured "PTAB proceedings on file" block states the USPTO ODP API returns no AIA trial proceedings for this patent. That is incomplete with respect to the public record. Web search surfaced three proceedings naming '106 as the challenged patent (plus a fourth, joined matter), all confirmed by PTAB papers, litigation complaints, and the Federal Circuit opinion. The ODP gap is likely an indexing lag for pre-2018 trials. I treat the search results as controlling per the operating rules, and I list nothing I cannot source.

Proceedings overview

Three proceedings name US 7,765,106 as the challenged patent — two IPRs (one with a joined second petitioner) and one CBM. Breakdown by status: claims invalidated — 1 (IPR2015-00546, all claims 1–8 held unpatentable); settled/terminated as to a joined petitioner — 1 (IPR2015-01815); institution denied — 1 (CBM2014-00161). There are no active proceedings.

Bottom line for a defendant: This patent is dead, not hardened. Every one of claims 1–8 was canceled by the PTAB in IPR2015-00546 (FWD 2016-07-27), and the Federal Circuit affirmed on 2018-07-13. It is not a "survived two IPRs" patent — it is a "did not survive one" patent. Any demand letter, complaint, or Orange Book listing that relies on claims of '106 has no live claims to assert. The remaining defensive questions are about sibling patents in the same family, not '106.

IPR2015-00546 — [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) & Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review
• Filed: 2015-01-08 (accorded filing date; petition challenges claims 1–8)
• Status: Final Written Decision — All Claims Unpatentable. (Case terminated; patent owner's request for rehearing denied 2016-12-22.)
• Judge panel: Brian P. Murphy, Jacqueline Wright Bonilla, Jon B. Tornquist, and Susan L. C. Mitchell (Administrative Patent Judges). Wockhardt's joined matter was handled by the panel of Bonilla, Mitchell, and Murphy.
• Petition grounds: Obviousness under 35 U.S.C. § 103 of claims 1–8 over the "Advisory Committee Art" ("ACA materials," Exs. 1003–1006) — the FDA's publicly posted Xyrem® advisory-committee background materials, briefing booklet, clinical safety review, and the video/transcript describing a proposed restricted distribution system. Trial was instituted on a single obviousness ground.
• Institution decision: Instituted 2015-07-28 on the single § 103 ground over the ACA materials. The Board found the Federal Register notice (66 Fed. Reg. 24,391, 2001-05-14) plus the hyperlinked FDA website rendered the ACA materials publicly accessible printed publications under pre-AIA § 102(b), and that a person of ordinary skill would have been motivated to locate them.
• Final Written Decision: Issued 2016-07-27 (Paper 70). The Board held claims 1–8 unpatentable as obvious — i.e., all independent claims (1, 3, 5, 7) and all dependent claims (2, 4, 6, 8) canceled. The '106 FWD was issued alongside the companion decisions in IPR2015-00545 ('182), -00547 ('107), -00548 ('059), -00551 ('988), and -00554 ('730); a combined oral hearing was held 2016-04-19. Reasoning summarized at the Federal Circuit (895 F.3d 1347): the ACA materials were a § 102(b) printed publication because they were disseminated via the Federal Register, publicly accessible for at least two months before the critical date, and carried no expectation of confidentiality. Decision on request for rehearing denied 2016-12-22 (Paper 74).
• Settlement / termination: Co-petitioner Wockhardt Bio AG (joined via IPR2015-01815) was terminated from the proceeding on 2016-05-05; Jazz and Par later settled (Par dropped out of the appeal). The Amneal/Par merits were not settled — they were decided on the merits.
• Appeal: Appealed to the Federal Circuit and affirmed. The '106 FWD was among the decisions consolidated in Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018), decided 2018-07-13 (consolidated Nos. 2017-1671, -1673, -1674, -1675, -1676, -1677, and -2075; panel of Newman, Lourie, Reyna; opinion by Lourie). The sole contested issue was whether the ACA materials qualified as a § 102(b) printed publication; the Court held they did, rejected any indexing/searchability requirement, and affirmed the obviousness holdings. Opinion: https://www.courtlistener.com/opinion/[4516711](/patent/4516711)/jazz-pharmaceuticals-inc-v-amneal-pharmaceuticals-llc/
• Defensive value: Maximal. Claims 1–8 of '106 are canceled and the cancellation is judicially final. Any infringement theory built on '106 is legally baseless. If a plaintiff sues you on '106, you can move to dismiss or seek summary judgment on the cancellation, and a fee/sanctions argument under 35 U.S.C. § 285 may be available if the plaintiff knew the claims were canceled.

IPR2015-01815 — Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc. (joined)

• Type: Inter Partes Review (instituted and joined to IPR2015-00546 under 35 U.S.C. § 315(c))
• Filed: 2015-08-27 (accorded filing date)
• Status: Institution granted and joinder granted (2015-10-30); terminated as to Wockhardt (2016-05-05). Plain English: Wockhardt rode the Amneal/Par trial and then exited before the FWD.
• Judge panel: Jacqueline Wright Bonilla, Susan L. C. Mitchell, Brian P. Murphy.
• Petition grounds: Obviousness under § 103 of claims 1–8 over the identical ACA materials and the same single ground already instituted in IPR2015-00546. The Board expressly found the Wockhardt petition "identical to the instituted Amneal/Par IPR Petition" in arguments, evidence, and ground.
• Institution decision: 2015-10-30 — instituted and joined. The Board granted joinder because Wockhardt filed within one month of the -00546 institution date, agreed to adopt Amneal/Par's papers and the same expert testimony, and agreed not to seek separate discovery or alter the trial schedule.
• Final Written Decision: None issued in -01815 itself. The joined proceeding resolved via the IPR2015-00546 FWD of 2016-07-27, which is listed in the -01815 docket as the operative Final Written Decision (the Board entered the same FWD in both cases).
• Settlement / termination: Wockhardt was terminated as to the '106 IPR on 2016-05-05; the matter formally closed 2017-01-03. Per counsel (Duane Morris, who represented Wockhardt), Wockhardt settled prior to the Federal Circuit decision and was not a party to the appeal. Settlement terms are confidential.
• Appeal: No — Wockhardt settled and did not appeal; the appeal was prosecuted by Jazz against Amneal (and, until settlement, Par).
• Defensive value: Same as -00546 for '106 — Wockhardt's joinder added no independent claim outcome, but it confirms a second, independent generic filer reached the same § 103 attack without modifying it. For a current defendant, Wockhardt's privity chain matters for § 315(e)(2) estoppel analysis (see below).

CBM2014-00161 — Roxane Laboratories, Inc. & Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Type: Covered Business Method (CBM) Review (AIA § 18)
• Filed: 2014-08-04
• Status: Not Instituted (Denied). Plain English: the Board refused to even start the trial, holding '106 is not a CBM patent.
• Judge panel: Lora M. Green, Brian P. Murphy, and Jon B. Tornquist. Opinion by Murphy.
• Petition grounds: Claims 1–8 challenged under § 101 (abstract idea/ineligible subject matter), § 102(b) anticipation, and § 103(a) obviousness — including over the same ACA materials. (Petitioners went the CBM route specifically because § 101 cannot be raised in an IPR.)
• Institution decision: Denied 2015-02-09 (Paper 16). The Board held the claims, read as a whole, recite checks and controls on shipping/mailing a prescription drug to prevent abuse and diversion — not a "financial product or service." Petitioners' argument that filling a prescription inherently involves insurance/payment was deemed conclusory and unsupported by the claim language; the Board refused to expand CBM to anything "used in commerce." Decision: https://natlawreview.com/article/roxane-labs-and-par-pharm-v-jazz-pharm-denying-institution-cbm2014-00161-175
• Final Written Decision: None — no trial was instituted.
• Settlement / termination: Terminated on denial of institution.
• Appeal: None. A denial of institution is non-appealable (Cuozzo-line authority); petitioners instead pursued the § 103 IPRs.
• Defensive value: Historically significant but now moot for '106 — the same claims died in IPR2015-00546. Take note, however, of the teaching: you cannot reach § 101 on Jazz's distribution patents through the CBM door. Any § 101 challenge to a surviving family member (see below) must be litigated in district court, not the PTAB.

Strategic summary

Claim status of '106. All challenged claims were canceled; none were sustained. Because the IPR petition covered claims 1–8 (the entire claim set), there are no untested claims in the '106 patent itself — claims 1, 3, 5, 7 (independents) and 2, 4, 6, 8 (dependents) are all held unpatentable, affirmed. The cancelation is final and non-appealable as of 2018-07-13 (any further review would have required certiorari). The patent shows "Expired – Fee Related" with an adjusted expiration of 2027-06-19, and was Orange-Book listed to 2024-06-16, but neither matters — there is nothing left to enforce.

Estoppel landscape. Under 35 U.S.C. § 315(e)(2) and the CBM-specific estoppel of AIA § 18, Amneal, Par, Wockhardt, Roxane, and their privies are estopped in district court from asserting any ground they raised or reasonably could have raised in the IPRs. Because IPR grounds are limited to § 102/§ 103 over patents and printed publications, that estopped set is narrow: § 101 eligibility, § 112 (written description/enablement/definiteness), public-use and on-sale art, inequitable conduct, and prosecution laches are NOT estopped for those parties. Estoppel does nothing for brand-new defendants who were not petitioners or privies — they face no § 315(e)(2) bar, but they also have nothing to defend, since the claims are canceled. Watch the privity perimeter (e.g., an acquirer of a co-petitioner's ANDA, or a contract manufacturer) if you are assessing whether a new suit is collusive.

Pattern signals. The same small group of generic filers attacked this family in a coordinated wave: Amneal + Par filed the January 2015 IPR set (IPR2015-00545 through -00554 and -01903, covering '182, '106, '107, '059, '988, '730, and '963) on a single, shared theory (ACA materials as § 102(b) prior art), and Wockhardt filed a parallel joinder set (IPR2015-01813 through -01820). No defensive aggregator (e.g., Unified Patents) appears in the PTAB chain — this was generic-industry-driven, not a defensive-aggregator campaign. Jazz pushed the appeal aggressively (it briefed and argued the printed-publication issue at the Federal Circuit and lost), and the family shows a long history of serial continuation filing to keep distributing rights alive. That prosecution strategy is the real risk surface: the '106 patent is gone, but newer family members and later-filed REMS patents (e.g., US 11,456,081, "Sensitive drug distribution systems and methods," and the Avadel-facing patents litigated into 2024) are separate enforcement vehicles that the '106 outcome does not automatically kill.

Recommended next steps

1. If a plaintiff asserts '106 against you, the case is over on the merits — move immediately. The operative disposition is the IPR2015-00546 Final Written Decision (2016-07-27), holding claims 1–8 unpatentable, affirmed at 895 F.3d 1347 (Fed. Cir. 2018). Quote the FWD's "all claims unpatentable" disposition and the Federal Circuit's affirmance, and consider § 285 fees if the asserter had notice of cancelation. Verify current claim status on USPTO Patent Center / PTAB E2E before filing (search case IPR2015-00546) so you can cite the certificate of cancelation.

2. Do not stop at '106. Because Jazz relied on continuation filings, confirm the status of sibling family patents — especially US 7,797,171 ('771), which is in the same priority family but was not among the seven patents challenged in the Amneal/Wockhardt IPR wave and currently shows as active to 2026-07-19; its validity has not been tested by an AIA trial and the '106 result does not bind it. Treat '771 as the live risk, and screen the newer REMS-family patents ('081 and successors) separately.

3. No active proceedings means no trial-stage milestones to track — there is no institution deadline, oral hearing, or FWD due date pending on '106. The absence of a current IPR is not a meaningful signal here (as it sometimes is for well-asserted patents), because the patent was already fully invalidated and its Orange Book life has lapsed.

4. Escalate any newly-filed PTAB matter on '106 or '771 if your search shows one post-dating this analysis; the ODP index appears not to carry the 2014–2016 '106 trials, so rely on PTAB E2E and CourtListener dockets rather than ODP for this patent.

Confidence notes: Claim-level outcome (claims 1–8 all unpatentable), filing/institution/FWD dates, and the Federal Circuit affirmance are well-sourced and high-confidence. The precise Federal Circuit docket number for the '106 appeal is not separately confirmed — '106 was one of the consolidated appeals (Nos. 2017-1671 through -1677 and -2075) decided under the single lead caption Jazz Pharm., Inc. v. Amneal Pharm., LLC; I have not verified which individual docket corresponds to the '106 FWD, so I do not assign one. The Char of which APJ authored the -00546 FWD is likewise not confirmed; I list the panel as docketed.

I'll research the assignment record and litigation context before assembling the analysis.

Now let me look for the specific reel/frame records and correspondent data.

Inventors

Data-availability note up front: the per-record view of USPTO Assignment Center (reel/frame numbers and the correspondent of record on each recording) could not be retrieved with the tools available for this session. Every assignor/assignee/conveyance/date below is taken from the recorded-assignment events tabulated on Google Patents' legal-events panel for US 7,765,106, which mirrors the USPTO record but omits reel/frame and correspondent fields. Reel/frame citations should be read as not retrieved, not as "none exists." Litigation/context facts are cited to court and SEC documents.

Grounds for the Orphan Medical employer call:

• The priority application in this family, Ser. No. 10/322,348 (filed 2002-12-17), "Orphan Medical filed on December 17, 2002" — In re Xyrem (Sodium Oxybate) Antitrust Litigation, No. 3:20-md-02966, Doc. 1 ¶ 86 (N.D. Cal.).
• Reardan appears in Orphan Medical's GHB portfolio: PlainSite record for USPTO Patent Assignment 28567/317 (Reel/Frame 28567/317), Cook, Hamilton, Danielson, Goderstad and Reardan → Orphan Medical, Inc., executed 2000-06-27, recorded 2012-07-17 — https://www.plainsite.org/patents/assignment.html?id=[5603907](/patent/5603907). (This is a related, earlier assignment for a different Orphan Medical patent, cited only to corroborate Reardan's employment relationship; it is not a record in the '106 chain.)
• Foreign-family search records list the trio as "ENGEL P A; GAGNE B; REARDAN D T" under assignee "ORPHAN MEDICAL INC."

Unusual-pattern check: No evidence that the inventors departed the original assignee within 12 months of filing, and no fire-sale-triggering abandonment. The three inventors are Minnesota-based Orphan Medical personnel; the entity that acquired the family (Jazz Pharmaceuticals, Inc.) was a separate Palo Alto company, so "inventor departure" is not a meaningful signal here. The front-page assignee of the issued patent is JPI Commercial, LLC, Palo Alto, CA — a change from the Orphan Medical applicant of the 2002 parent, reflecting the post-acquisition corporate shuffle (see timeline), not inventor departure.

Original assignee

Named on the issued patent (2010-07-27): JPI Commercial, LLC, Palo Alto, CA — a Delaware LLC described in Jazz's own SEC filings as "a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc." with principal offices at 3180 Porter Drive, Palo Alto, CA 94304 (Amendment No. 3 to License Agreement with Solvay Pharmaceuticals, Ex. 10.78, Jazz 10-K/A FY2008 — https://investor.jazzpharma.com/).

• Line of business: pharmaceutical distribution/commercialization; JPI Commercial was the Jazz contracting entity for Xyrem and Luvox licensing arrangements (it is the named party on Jazz's Solvay license amendments and on the 2010 Anchen settlement/sub-license).
• Product embodying the claims: Yes. The '106 family is the "Xyrem REMS / RiskMAP patents" — the exclusive central pharmacy and patient/prescriber registry system through which Xyrem (sodium oxybate oral solution) was actually dispensed. The REMS program (originally "RiskMAP," built with FDA) is described in the specification and was implemented commercially through Express Scripts Specialty Distribution Services ("ESSDS"). See In re Xyrem Antitrust Litig., Doc. 1 ¶¶ 74–76, 86–89.
• Current status of the operating group: Operating. Jazz Pharmaceuticals, Inc. remains an active NASDAQ-listed specialty pharma (Jazz Pharmaceuticals plc is the 2012-created Irish holding parent). Google Patents now lists Current Assignee: Jazz Pharmaceuticals Inc. No bankruptcy, no dissolution. (Note the 2009 near-insolvency episode described at ¶ 3 of the Xyrem antitrust complaint is historical context for the LB I Group security interest, not a bankruptcy sale.)

Assignment timeline

All entries below are from the Google Patents legal-events record for US 7,765,106 (https://patents.google.com/patent/US7765106/en#legal-events). Execution dates and reel/frame numbers were not surfaced; the dates shown are the recording/event dates in that table. Correspondent-of-record is not recoverable from this data set and is reported as not retrieved rather than guessed.

Baseline (non-assignment events, for reference)

• 2004-11-02 — Application Ser. No. 10/979,665 filed (divisional of 10/322,348, now US 7,668,730); recorded filer JPI Commercial LLC.
• 2005-04-28 — US 20050090425A1 published.
• 2010-07-27 — US 7,765,106 B2 issued; assignee of record JPI Commercial, LLC.

Recorded assignments

• 2005-07-29 (recorded) — Reel not retrieved

  • Conveyance: Security Interest
  • Assignor: Twist Merger Sub, Inc.
  • Assignee: LB 1 Group Inc.
  • Correspondent: not retrieved
  • Context: Securitization — Lehman-affiliated lender taking a security interest in connection with the leveraged acquisition of Orphan Medical (Twist Merger Sub, Inc. is the merger sub in the April 18, 2005 Agreement and Plan of Merger — Jazz 10-K Ex. 2.1).

• 2008-04-04 (recorded) — Reel not retrieved

  • Conveyance: Security Agreement
  • Assignor: JPI Commercial, LLC
  • Assignee: LB I Group Inc.
  • Correspondent: not retrieved
  • Context: Securitization — collateral grant under the March 14, 2008 Senior Secured Note and Warrant Purchase Agreement among Jazz, JPI Commercial and the purchasers (Jazz 10-K/A FY2008, Ex. 4.5A).

• 2010-06-30 (recorded) — Reel not retrieved

  • Conveyance: Security Agreement
  • Assignor: Jazz Pharmaceuticals, Inc.
  • Assignee: Silicon Valley Bank
  • Correspondent: not retrieved
  • Context: Securitization — venture-debt collateral package.

• 2010-06-30 (recorded) — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor: LB I Group, Inc.
  • Assignee: JPI Commercial, LLC
  • Correspondent: not retrieved
  • Context: Release of security — LB I lien discharged.

• 2010-11-12 (recorded) — Reel not retrieved

  • Conveyance: Merger
  • Assignor: Orphan Medical, Inc.
  • Assignee: Orphan Medical, LLC
  • Correspondent: not retrieved
  • Context: Internal reorganization — conversion of the legacy Minnesota acquiring corporation into an LLC five years post-merger.

• 2010-11-12 (recorded) — Reel not retrieved

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Orphan Medical, LLC
  • Assignee: JPI Commercial, LLC
  • Correspondent: not retrieved
  • Context: Internal reorganization — title moved to the Jazz commercial subsidiary.

• 2010-11-17 (recorded) — Reel not retrieved

  • Conveyance: Assignment of Assignors Interest
  • Assignor: JPI Commercial, LLC
  • Assignee: Jazz Pharmaceuticals, Inc.
  • Correspondent: not retrieved
  • Context: Internal reorganization — upstream assignment to the listed parent; this is the link that puts the operating parent of record.

• 2010-11-26 (recorded) — Reel not retrieved

  • Conveyance: Merger (repeat of the 2010-11-12 merger recording)
  • Assignor: Orphan Medical, Inc. → Assignee: Orphan Medical, LLC
  • Correspondent: not retrieved
  • Context: Internal reorganization / re-recording — duplicate chain, consistent with a corrected or re-recorded package.

• 2010-11-26 (recorded) — Reel not retrieved

  • Conveyance: Assignment of Assignors Interest (repeat of the 2010-11-12 recording)
  • Assignor: Orphan Medical, LLC → Assignee: JPI Commercial, LLC
  • Correspondent: not retrieved
  • Context: Internal reorganization / re-recording.

• 2010-12-22 (recorded) — Reel not retrieved

  • Conveyance: Assignment of Assignors Interest (repeat of the 2010-11-17 recording)
  • Assignor: JPI Commercial, LLC
  • Assignee: Jazz Pharmaceuticals, Inc.
  • Correspondent: not retrieved
  • Context: Internal reorganization / re-recording.

• 2011-12-30 (recorded) — Reel not retrieved

  • Conveyance: Release
  • Assignor: Silicon Valley Bank
  • Assignee: Jazz Pharmaceuticals, Inc.
  • Correspondent: not retrieved
  • Context: Release of security — SVB payoff.

• 2012-08-06 (recorded) — Reel not retrieved

  • Conveyance: Security Interest
  • Assignors: EUSA Pharma (USA), Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc.
  • Assignee: Barclays Bank PLC, as Collateral Agent
  • Correspondent: not retrieved
  • Context: Securitization — cross-border credit facility collateral.

• 2015-06-19 (recorded) — Reel not retrieved

  • Conveyance: Security Agreement
  • Assignors: Jazz Pharmaceuticals International III Limited; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals Ireland Limited; Jazz Pharmaceuticals, Inc.
  • Assignee: Bank of America, N.A., as Collateral Agent
  • Correspondent: not retrieved
  • Context: Securitization — the June 18, 2015 Credit Agreement among Jazz Pharmaceuticals plc, Jazz Securities Limited, Jazz Pharmaceuticals, Inc., Jazz Financing I Limited, Jazz Pharmaceuticals Ireland Limited and Bank of America (Jazz 10-K, Ex. 10.13A).

• 2015-07-09 (recorded) — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor: Barclays Bank PLC
  • Assignees: Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc.; EUSA Pharma (USA), Inc.
  • Correspondent: not retrieved
  • Context: Release of security — Barclays lien discharged.

• 2021-05-05 (recorded) — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor: Bank of America, N.A.
  • Assignees: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals International III Limited; Celator Pharmaceuticals, Inc.; Cavion, Inc.; Jazz Pharmaceuticals Ireland Limited
  • Correspondent: not retrieved
  • Context: Release of security — BofA collateral released across the Jazz group.

No assignment event appears for these two well-known Jazz Ireland recordings in this chain (cited for comparison only, from a different patent, IPR2016-00546 Paper 8): inventor Mark Eller → Jazz at Reel/Frame 30836-953 (recorded 2013-07-09) and Jazz → Jazz Pharmaceuticals Ireland Ltd. at Reel/Frame 33480-220 (recorded 2014-07-29). This shows the Jazz group's house practice of parking Xyrem-family patents in an Irish affiliate; no equivalent Jazz → Jazz Ireland recording was surfaced for the '106 patent, although the PTAB docket for IPR2015-00546 lists "Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED" while Google Patents lists current assignee as "Jazz Pharmaceuticals Inc." That ownership discrepancy is unresolved on the evidence available.

Chain summary: Orphan Medical, Inc. → (Merger into Jazz via Twist Merger Sub, June 2005) → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc., with security interests running in parallel to LB I Group → Silicon Valley Bank → Barclays → Bank of America, each released. Every recorded assignor and assignee is an operating Jazz-group entity or a secured lender. There is no licensing-only LLC anywhere in the chain.

Timeline diagram

timeline
    title Ownership of US 7765106
    2002 : Priority application filed by Orphan Medical
    2004 : Divisional application filed
    2005 : Jazz acquires Orphan Medical
    2005 : LB I Group security interest recorded
    2008 : LB I Group security agreement recorded
    2010 : Patent issues July 27
    2010 : Orphan Medical merged into Orphan Medical LLC
    2010 : Assigned to JPI Commercial LLC
    2010 : Assigned to Jazz Pharmaceuticals Inc
    2010 : Jazz sues Roxane in New Jersey
    2011 : Silicon Valley Bank release recorded
    2012 : Barclays security interest recorded
    2015 : Bank of America security agreement
    2016 : PTAB invalidates the claims
    2018 : Federal Circuit affirms invalidity
    2021 : Bank of America releases security interest

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The chain moves only between operating group entities and lenders: Orphan Medical, Inc. (Minnetonka, MN operating pharma); JPI Commercial, LLC (Delaware LLC but a wholly-owned subsidiary of Jazz Pharmaceuticals, Inc. with the parent's 3180 Porter Drive, Palo Alto address — see the Solvay license amendments at Ex. 10.78/10.79 of Jazz's FY2008 10-K/A); Jazz Pharmaceuticals, Inc.; Jazz Ireland entities. JPI Commercial is the named contracting party on Jazz's commercial licenses and on a 2010 settlement/sub-license, i.e., a trading entity, not a passive licensing shell. No "IP/Patents/Ventures/Holdings" suffix, no registered-agent-service address, no single-purpose assignee.

2. Known asserter in the chain — not present. The recorded assignees (JPI Commercial, Jazz Pharmaceuticals, Jazz Ireland entities, EUSA Pharma) and lienholders (LB 1/LB I Group, Silicon Valley Bank, Barclays Bank PLC, Bank of America) appear on none of the named NPE lists (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Unified Patents' patent page for US 7,765,106 (https://portal.unifiedpatents.com/patents/patent/[7765106](/patent/7765106)) lists Jazz Pharmaceuticals Inc as assignee and shows the '106 patent in the petitioner side of IPR2015-00546 — the USPTO-side record of Jazz as a defendant in validity challenges, not as an NPE.

3. Repeat correspondent across the chain — unclear / not retrievable. USPTO Assignment Center's correspondent field was not accessible in this session, so recurrence cannot be tested. What is observable is that Jazz's litigation counsel of record on the '106 patent are well-known operating-company firms — Quinn Emanuel Urquhart & Sullivan and Jones Day for appellant Jazz in Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. 2018) — which is the opposite of the single-repeat-player NPE pattern. No finding either way on the recording agents.

4. Cascading transfers — present but benign form. Three near-identical recordings were made twice within six weeks in late 2010: Orphan Medical, Inc.→Orphan Medical, LLC merger (2010-11-12, repeated 2010-11-26), Orphan Medical, LLC→JPI Commercial, LLC (2010-11-12, repeated 2010-11-26), and JPI Commercial, LLC→Jazz Pharmaceuticals, Inc. (2010-11-17, repeated 2010-12-22). That is a re-recorded internal reorg package, not chained shell LLCs: every assignee shares the same corporate principal (Jazz) and the same Palo Alto address, and the timestamps are months, not years, apart from the issuance of the patent on 2010-07-27. There is no evidence of shared registered-agent addresses among unrelated parties.

5. Pre-litigation transfer — present, but as standing housekeeping, not NPE transfer. The 2010-11/12 recordings (issued patent 2010-07-27; Orphan→LLC→JPI→Jazz) sit within weeks of Jazz's first Xyrem ANDA suit against Roxane, filed 2010-11-22 as No. 2:10-cv-06108 (In re Xyrem Antitrust Litig., Doc. 1 ¶ 92; Google Patents litigation link for case 2:10-cv-06108). Roxane's Paragraph IV notice was dated 2010-10-14. The transfers cleaned up title in an existing corporate group on the eve of suit — the classic "clean standing record" — but the transferees are operating Jazz entities, so this does not convert the chain into an NPE arrangement.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 sale of this patent in the record. The closest facts are (a) the Lehman-affiliated LB I Group security interest recorded 2005-07-29 and the LB I security agreement recorded 2008-04-04, both released 2010-06-30, and (b) the antitrust plaintiffs' allegation that Jazz was "on the verge of bankruptcy" in 2009 (In re Xyrem Antitrust Litig., Doc. 1 ¶ 3). Neither produced a patent sale in proceedings.

7. Privateering — not present. Jazz, not a separate NPE, filed the infringement actions in its own name: Roxane (D.N.J. 2:10-cv-06108, Nov. 22, 2010), Amneal (D.N.J. 2:13-cv-00391, AO-120 naming Jazz Pharmaceuticals, Inc. as plaintiff), and the further New Jersey actions 2:12-cv-06761, 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, 2:18-cv-00029, plus N.Y. E.D. 2:17-cv-04439. No transfer-to-asserter step intervenes.

8. Defensive aggregator — not present. No RPX, AST, LOT Network, Unified Patents or OIN entity takes title at any point; the chain terminates in the Jazz group, with only Bank of America's 2021-05-05 release of its collateral interest.

Outcome note (relevant to the "is this a troll?" question): the asserted '106 claims were cancelled in substance before expiry — IPR2015-00546 Final Written Decision 2016-07-27, affirmed in Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. 2018). Google Patents lists the patent as "Expired – Fee Related" with an adjusted expiration of 2027-06-19; the Orange Book listing described in the Labaton Sucharow/Roxane complaint shows 06/16/2024 with patent use code U-1009. Both figures are recorded as stated; I have not reconciled them.

Verdict

Operating-company assertion.

Justification: every recorded assignee in the chain is an operating member of the Jazz Pharmaceuticals group — the byline assignee JPI Commercial, LLC (a wholly-owned Jazz subsidiary at 3180 Porter Drive, Palo Alto, per Jazz's own FY2008 10-K/A exhibits), then Jazz Pharmaceuticals, Inc. by the upstream recording of 2010-11-17 (re-recorded 2010-12-22) — with the intervening Nov./Dec. 2010 Orphan Medical, Inc.→Orphan Medical, LLC→JPI Commercial, LLC recordings being an internal reorg of an entity Jazz had already acquired in June 2005 via Twist Merger Sub, Inc. (captured in the 2005-07-29 LB 1 Group security-interest recording). Jazz simultaneously shipped the claimed subject matter (Xyrem dispensed through the exclusive central pharmacy/registry REMS described in the specification) and sued real generic competitors in its own name — Roxane at 2:10-cv-06108 (2010-11-22) and Amneal at 2:13-cv-00391 — rather than transferring to an NPE. None of the eight NPE signals are supported: no shell assignee, no known asserter, no defensive aggregator, and the only debt-side links (LB I Group, Silicon Valley Bank, Barclays, Bank of America) are ordinary security interests, all released (last release recorded 2021-05-05).

Verification: search the patent number at USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (or the legacy interface https://assignment.uspto.gov/patent/index.html) — and compare the legal-events tab at https://patents.google.com/patent/US7765106/en. I was unable to pull the reel/frame and correspondent fields directly; a manual Assignment Center lookup is required to complete the "repeat correspondent" test, which is the one signal this analysis leaves genuinely unresolved.

I'll research the prior-art citations for US 7,765,106, since the citation list in the provided text was truncated at "US61...".

Good — I found the front-page reference list. Let me pull the full "References Cited" list and the key IPR/litigation prior art (the art that actually invalidated the claims).

Let me retrieve the complete front-page reference list and details on the key references.

I hit my tool-step limit while gathering full reference texts, so this analysis is built from (a) the authoritative patent text you supplied, (b) the front-page "References Cited" list recovered from the printed patent, FreePatentsOnline, and DocShare, and (c) the IPR2015-00546 / Federal Circuit record. Where I could not open a reference's full text, I say so rather than guessing at its disclosure.

Prior Art Analysis — US 7,765,106 B2 ("Sensitive drug distribution system and method")

0. Framing and caveats (read first)

Critical date. The '106 patent issued 2010-07-27 from App. No. 10/979,665, filed 2004-11-02, as a divisional of App. No. 10/322,348, filed 2002-12-17. The effective priority date of the claims is therefore December 17, 2002, and the pre-AIA § 102(b) critical date is December 17, 2001. The '106 patent is pre-AIA (filed/priority before March 16, 2013), so pre-AIA §§ 102(a), (b), (e) and 103 apply.

Three important drafting/status flags:

1. The task premise vs. the record. You asked which references anticipate under § 102. The decisive validity event for this patent was IPR2015-00546, in which the PTAB held all claims 1–8 unpatentable as obvious under § 103 — over the Advisory Committee Art, sometimes alone and sometimes in view of other references (e.g., Korfhage). The Federal Circuit affirmed (Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. July 13, 2018)). Nothing in the '106 record was decided as a § 102 anticipation. So below I identify what each reference could disclose element-by-element, and I flag § 102 candidacy clearly, but I do not invent anticipations the tribunals never found.
2. Date conflict in the earlier section (flagged, unresolved). The prior section lists the IPR2015-00546 final written decision as "July 27, 2016." The Federal Circuit's own footnote cites it as Par Pharm., Inc. v. Jazz Pharm., Inc., No. IPR2015-00546, 2016 WL 7985429 (P.T.A.B. Dec. 22, 2016); RPX lists "Final: 07/27/2016"; the class-action complaint says July 27, 2016. I cannot reconcile these and do not rely on the exact date.
3. Date conflict in the prompt (flagged). Your task header says "Current Date: April 26, 2026," while the system date is October 1, 2026. This does not change the analysis (the art and the appeal all predate both).

Two references on the face of the patent are NOT prior art — do not treat them as such:

1. The references cited ON THE FACE of the '106 patent

These are the references the Examiner considered during prosecution (the "References Cited" / Google "Citations (43)" set). Note that many of the 2003–2005 published applications cannot be § 102(a)/(b) art because they published after the Dec. 17, 2002 priority date; they could only be § 102(e) art if their underlying U.S. applications were filed before the invention date. I mark that.

1A. U.S. Patents (retrieved verbatim from the authoritative text and FPO)

Note: FreePatentsOnline's table also re-lists several of the above as "US Patent References" alongside their published-application equivalents (e.g., 2003/0144876 = Kosinski; 2004/0117126 = Fetterman; 2004/0122712 & /0122713 = Hill; 2004/0176985 = Lilly). I have not double-counted them.

1B. U.S. Published Applications cited (2001–2005)

1C. Non-patent literature on the face

The Google Patents "Citations (43)" set contains non-patent literature, but the authoritative text you supplied truncates at "US61…", so I could not enumerate the remaining ~30 citations (including any NPL items). I flag this as a gap rather than guess.

2. The prior art that ACTUALLY DECIDED the '106 patent (IPR2015-00546)

This is the art that matters. The PTAB held all of claims 1–8 unpatentable, and the Federal Circuit affirmed 895 F.3d 1347 (2018).

2A. The Advisory Committee Art ("ACA materials") — the primary reference

Full citation (four documents, treated as one collective body of art):

1. FDA Peripheral and Central Nervous System Drugs Advisory Committee — Xyrem meeting transcript and slides (meeting held June 6, 2001; posted on the FDA website by October 4, 2001).
2. FDA Preliminary Clinical Safety Review of Xyrem (sodium oxybate) (posted before the meeting, ~June 5, 2001).
3. Xyrem Briefing Booklet (cover states "AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION"; posted ~June 5, 2001).
4. Xyrem video and transcript describing the proposed distribution system (posted ~June 5, 2001).

• Public-accessibility anchor: Notice of the advisory committee meeting, 66 Fed. Reg. 24,391 (May 14, 2001), which included a hyperlink to the FDA docket page where the materials were posted.

Dates: materials made publicly accessible no later than ~June 5–October 4, 2001 — more than one year before the December 17, 2001 critical date, and more than a year before the December 17, 2002 priority date. § 102(b) printed publication.

Description: The ACA collectively discloses the Xyrem restricted-distribution/risk-management program — centralized distribution, prescriber and patient registration/verification, patient and prescriber education, and diversion/abuse monitoring — i.e., the very subject matter of the '106 claims.

§ 102 / § 103 analysis: This is the closest thing to an anticipatory disclosure in the record. The Board found the ACA collectively taught or suggested all limitations of the instituted claims of the '730 family, and the Federal Circuit affirmed — but the ground was § 103 obviousness (the ACA considered together, and combined with Korfhage for the multi-computer "distributed database" limitation), not § 102 anticipation. Accordingly, on the record: the ACA materials are strong § 102(b) art against claims 1, 3, 5, 7 and their dependents 2, 4, 6, 8; the tribunal's holding, however, was obviousness.

Nothing about "2026 CAFC activity" for this patent appears in the record; the controlling decision is the July 13, 2018 affirmance.

2B. Secondary references used in the § 103 combinations

3. Bottom line: § 102 vs. § 103, and which claims

• No single reference in the '106 record was held to anticipate any claim under § 102. The decisive invalidity was § 103 obviousness over the ACA materials, affirmed at 895 F.3d 1347.
• All 8 claims (1–8) were held unpatentable — the four independent claims (1, 3, 5, 7) and the four dependent claims (2, 4, 6, 8).
• For a § 102 (anticipation) theory, the only realistic single-reference candidates are:
  • the ACA materials as a collective printed publication (against claims 1, 3, 5, 7 and dependents);
  • US 6,045,501 / US 6,757,784 (Celgene restricted-delivery patents) — but these lack the "exclusive central system/database" and "periodic reports" limitations, so they are § 103 art, not clean anticipations;
  • US 6,952,681 / US 2002/0042762 (McQuade, controlled-article tracking) and US 2003/0229519 (Eidex, fraud/abuse detection) — closest on the tracking/abuse-analysis elements, but each is missing other limitations (§ 103, not § 102).
• Most of the 2001–2005 published applications on the face of the patent are § 102(e)-only or § 103 art because they published after the Dec. 17, 2002 priority date, and US 7,668,730 and the Reardan 2005/02xxxxx publications are the applicant's own family documents and are not prior art at all.

4. Explicit uncertainties

1. I could not retrieve the full text of every cited reference, so the § 102 statements above are reasoned from the reference titles/known subject matter and the IPR/CAFC record, not from a limitation-by-limitation reading of each.
2. The Google "Citations (43)" list is truncated in the supplied authoritative text at "US61…"; I enumerated the front-page patent/application citations I could recover but cannot guarantee the list is complete.
3. The IPR2015-00546 final written decision date is reported inconsistently (Dec. 22, 2016 per the Federal Circuit footnote and Westlaw; July 27, 2016 per RPX and the class-action complaint; "2016 WL 7985429").
4. Petitioner identity is reported as Amneal/Par in the caption (the Federal Circuit cites Par Pharm., Inc. v. Jazz Pharm., Inc.) with Wockhardt joining via IPR2015-01815 — consistent with, but not identical to, the earlier section's note of the Amneal-vs-Par discrepancy.
5. No 2026 Federal Circuit docket activity for 7,765,106 was located; the controlling appellate authority remains the July 13, 2018 affirmance.

I'll research the cited prior art references from the Prior Art section to ground an obviousness analysis.

Let me examine the remaining cited references and the PTAB obviousness record.

Let me research the remaining prior-art references and the "Korfhage" reference used in the IPR.

Obviousness Analysis of U.S. Patent 7,765,106 Under 35 U.S.C. § 103

Framing note before the analysis: There is no need to reconstruct the §103 picture from first principles here — a §103 challenge to this patent has already been litigated to a final, affirmed judgment of unpatentability. PTAB IPR2015-00546 (Final Written Decision July 27, 2016) held all claims unpatentable, and the Federal Circuit affirmed in Jazz Pharmaceuticals, Inc. v. [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC), 895 F.3d 1347 (Fed. Cir. July 13, 2018). Everything below therefore builds on that record plus the references listed in the Prior Art section of the patent page, and identifies which cited references would independently support the same conclusion.

• https://insight.rpxcorp.com/ptab/2606-wockhardt-v-jazz-pharmaceuticals-incorporated-ipr-of-106
• https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf

1. Governing law and the critical date

• Pre-AIA §103 applies (the application was filed Nov. 2, 2004, and claims priority to Dec. 17, 2002; the '106 is a divisional of App. Ser. No. 10/322,348, which issued as US 7,668,730). The analysis uses the Graham v. John Deere factors (KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) controls on motivation).
• Critical date for §102(b) prior art: December 17, 2001 — the Federal Circuit expressly used this date when assessing the Xyrem Advisory Committee materials. (The '106's own priority chain runs to the Dec. 17, 2002 parent filing.)
• PHOSITA (as found by the Board, affirmed on appeal): "a pharmacist or computer scientist having familiarity with computerized drug distribution procedures." This is a broad skill level that materially affects the motivation analysis — such a person both reads the Federal Register/FDA materials and knows how to wire up a central pharmacy database.
• Key claim constructions adopted by the Board:
  • "exclusive central computer system" = "single or sole computer system"
  • "exclusive computer database" = "single or sole computer database"
  • "periodic reports" = reports "generated at regular intervals or intermittently" (rejecting Jazz's narrower reading)
  • "information identifying" (patient/drug/credentials) = not limited to the specification's enumerated lists, and "credentials" means at least two different types.

These constructions knock out the two arguments Jazz would otherwise run (that "periodic" requires a fixed schedule, and that the recited data fields are closed lists).

2. The claims to be analyzed

Claims 1, 3, 5, 7 are four substantially parallel independent claims that rise or fall together (claim 3 is the sodium-oxybate/narcolepsy species; claim 5 recites the "exclusive database" rather than "exclusive central computer system"; claim 7 differs only in minor wording, including the literal typo "allowed to prescribed"). Claims 2, 4, 6, 8 merely narrow the applicable control list to a subset that is itself already contained within the independent claims — so if the independents are obvious, the dependents add nothing.

Each independent claim reduces to seven steps: (A) exclusive intake of all prescriptions (all patients/all doctors) into an exclusive central computer system; (B) mandatory entry into an exclusive database for abuse/misuse/diversion analysis, so that all prescriptions are authorized only through that system/database; (C) centralized tracking and determination of "current and anticipated patterns" of abuse from periodic reports; (D) selection of "multiple controls" from a ~30-item Markush "group consisting of"; (E) authorization by that system to fill a controlled, approved prescription; (F) noting, based on the analysis/reports, a patient-specific potential for abuse/misuse/diversion; and (G) delivering the drug to treat the patient.

3. Prior art from the patent's own citation list, mapped to the claims

The "Prior Art" section lists 43 references. The core relevant ones, with what they contribute:

The unifying point is that every one of the "field of endeavor" references is directed to the same problem — controlled distribution and tracking of a drug that is dangerous if misused — and several (e.g., '501, '525) already implement a central computer-readable registry consulted before authorization to dispense.

4. The strongest and actually-adjudicated combination: the ACA materials

The primary ground on which the claims were invalidated was not a patent-vs-patent combination but the Xyrem "Advisory Committee Art" ("ACA"), the four documents associated with the June 6, 2001 FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting, publicly posted on the FDA website (hyperlinked from 66 Fed. Reg. 24,391 (May 14, 2001)) no later than October 4, 2001:

1. FDA Advisory Committee Transcript and Slides (Ex. 1003);
2. FDA Preliminary Clinical Safety Review of Xyrem (Ex. 1004);
3. Xyrem Briefing Booklet (Ex. 1005);
4. Video and transcript describing a proposed distribution system for Xyrem (Ex. 1006).

• The Board found these documents "collectively taught or suggested all limitations of the claims," including the single/exclusive central pharmacy-with-database architecture, the physician- and patient-registry elements, patient/physician education, and the reporting/monitoring controls.
• The Federal Circuit affirmed public accessibility, holding that the Notice "widely disseminated" the materials via hyperlink and specific navigation instructions, and that "neither indexing nor searchability is required" where dissemination is sufficient.
• Motivation to combine/consult: the Board found a PHOSITA "would have been familiar with the Federal Register and motivated to look for notices related to drug distribution, safety, or abuse prevention," and would have known Xyrem's active ingredient was abuse-susceptible — sufficient motivation to locate and use the materials.

This is the combination with the strongest evidentiary and precedential footing, because courts have already held it renders claims 1–8 obvious in this exact patent.

5. Secondary combination: Celgene thalidomide/ S.T.E.P.S. art + Pyxis + prescription-management art

If one prefers a patent-based §103 case (rather than regulatory publications), the combination is:

(a) Elsayed '501 (or the '720 improvement) as the primary reference — teaches:

• registering prescribers, pharmacies, and patients in a computer-readable medium (steps A–B);
• counseling/education of the at-risk population and informed consent (the education controls);
• consulting the medium and authorizing the pharmacy to fill only for verified patients (steps B, E);
• centralized record-keeping that the specification characterizes as enabling monitoring/control (step C).

(b) Pyxis '392 as the secondary reference — teaches a single drug-distribution center running a computer inventory-management program in electronic communication with the dispenser, providing end-to-end tracking, purchase-order generation, invoicing, and inventory reconciliation (the controlled-inventory-release, single-source-manufacture, and single-location distribution elements), and demonstrating that centralizing distribution through one computerized source was a known, conventional architecture.

(c) Advanced Health Med-E-Systems '539/'525 as the tertiary reference — teaches electronic prescription capture, prescriber identity/credential data, and drug-utilization/abuse alerts (the physician-credential, prescription-verification, and "flagging" controls).

(d) Azron '074 and Cunningham '507 — supply patient-history/registry and dispensing-tracking capability.

Motivation to combine (the KSR factors all point one way):

1. Same field of endeavor — all four address computerized control and tracking of drug distribution to prevent misuse/contraindicated use.
2. Same problem, recognized need — preventing "Dr. shopping, diversion, and pharmacy thefts" was a known problem, and the FDA/DEA were affirmatively demanding risk-management programs (as the ACA itself demonstrates).
3. Predictable results — combining a registry-based authorization method ('501) with a single-source computerized distribution/inventory system ('392) and electronic prescription management ('525) is "a combination of familiar elements according to known methods" yielding no more than predictable results (KSR).
4. Reasonable expectation of success — the thalidomide S.T.E.P.S. program and the Pyxis distribution network each independently worked, so a PHOSITA would expect the combination to work.

Important caveat — this combination has a known gap. The Board in the '106 IPR rejected the ground built on "Talk About Sleep" (TAS) in view of Honigfeld, Elsayed, and Lilly, reasoning that those references disclose a *centralized registration database but a de-centralized network permitting multiple registered pharmacies to dispense directly to patients. Translating: the limitation that decided that ground was "exclusive central computer system" = "single or sole computer system." So an Elsayed-based combination must be supplemented with a reference teaching the single-central-pharmacy model (which is exactly what the ACA supplies, and what Pyxis's single-distribution-center model can be argued to supply). Any §103 chart using Elsayed alone will stumble on claim step A.

6. Step-by-step element mapping (independent claim 1; claims 3/5/7 track it)

7. Objective indicia (secondary considerations)

• Jazz argued the patent was non-obvious, but the Board and the Federal Circuit did not credit a nexus to any secondary consideration. Xyrem's commercial success is attributable to the drug and its market exclusivity, not to the claimed distribution method (and the method itself was publicly disclosed a year and a half before the application — the Federal Circuit quoted petitioner's characterization: "the patentees told the public about their restricted drug distribution system for Xyrem then tried to patent it a year and a half later").
• The '963 sibling patent's Final Written Decision frames the outcome as "an invention, but one in which Patent Owner's right to exclude was compromised because too much time passed between first disclosure and the patent application priority filing date."
  • https://litigationtracker.law.georgetown.edu/wp-content/uploads/2025/01/Jazz-Pharmaceuticals-Inc._2021.07.23_DEFENDANTS-MOTION-FOR-PARTIAL-JUDGMENT-ON-THE-PLEADINGS.pdf

8. Bottom line

1. Claims 1–8 were held obvious and unpatentable, a holding affirmed at 895 F.3d 1347. The decisive combination was the ACA materials covering Exs. 1003–1006, which the Board found taught or suggested all limitations, including the construed "exclusive [single] central computer system."
2. A patent-based alternative — Elsayed '501 (Celgene) as primary, in view of Pyxis '392, Advanced Health Med-E-Systems '539/'525, and one of Azron '074 / Cunningham '507 — supplies every element, but requires an additional reference teaching the single/pharmacy-exclusive architecture to satisfy claim step A, because the Board expressly found the Elsayed/Honigfeld/Lilly family teaches de-centralized multi-pharmacy dispensing.
3. Motivation is strong under KSR: same field, same known problem (diversion/abuse of controlled substances), predictable combination of known elements, regulatory pressure from FDA/DEA, and a PHOSITA (pharmacist or computer scientist) with both the domain knowledge and the technical skill to combine them.
4. The dependent claims 2, 4, 6, 8 add nothing — their narrowed control list is a strict subset of the independent claims' list, so they are obvious for the same reasons.

Explicit uncertainties / limitations on this analysis

1. The citation list in the source page was truncated at the tenth entry ("US61…"). My reference-by-reference mapping covers the nine fully identified U.S. patents plus the "Families Citing"/"Cited By" entries I could verify; additional cited references beyond that point were not retrievable in this session and could add further support (or, in principle, teach away).
2. "Korfhage" — the Board's '963 decision combined the ACA with "Korfhage," but my search for its full identity was cut short by the tool-step limit; I cannot confirm its number or content. Treat the Korfhage reference as unverified.
3. Petitioner identity in IPR2015-00546 remains reported inconsistently (Amneal Pharmaceuticals LLC vs. Par Pharmaceutical, Inc.); the docket caption shows "Amneal Pharmaceuticals, LLC, Par Pharmaceutical, Inc., and Wockhardt Bio AG." I have not re-resolved it here; it does not affect the §103 substance.
4. I did not retrieve the full text of the IPR2015-00546 Final Written Decision. I have the institution decision's discussion of both the ACA ground (instituted) and the TAS ground (not credited), and the RPX record showing "All Claims Unpatentable." I cannot state from a primary source whether the FWD rested exclusively on ACA or adopted any dependent-ground analysis.
5. Purdue US 2008/0300902 A1 and Gold US 2010/0256984 A1 appear in the "Cited By" list but post-date the '106 priority date and therefore are not prior art against it; I have used them only to describe the later state of the art and have flagged them as such.
6. The expiration-date conflict flagged in the earlier sections (Google Patents "adjusted expiration 2027‑06‑19" vs. an Orange Book listing of 06/16/2024 vs. the printed patent's 1,645-day §154(b) adjustment with terminal disclaimer) is unresolved and is independent of the §103 question — but it does bear on whether any remaining term survives the invalidity holding.